Ibrutinib and Venetoclax Under Investigation as First-Line Combo in MCL

0 reviews

Caroline Seymour

Targeted Oncology

The combination of ibrutinib and venetoclax will be tested as frontline therapy in previously untreated patients with mantle cell lymphoma as part of the 3-part phase 3 SYMPATICO trial.

I'm interested in this

Share with others

Write the first review

Join now
to leave a review or read peer reviews!

Resource tags
Show all tags

Share with others

I'm interested